1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary

3.1. Market Outlook
3.2. Drug Class Outlook
3.3. Age Group Outlook
3.4. Distribution Channel Outlook
3.5. Competitor Outlook

4. Market Overview

4.1. Introduction

5. Market Dynamics

5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges

6. United States Anti-obesity Prescription Drugs Market, By Drug Class

6.1. Introduction
6.2. Bupropion and Naltrexone
6.3. Liraglutide
6.4. Lorcaserin
6.5. Orlistat
6.6. Phentermine and Topiramate

7. United States Anti-obesity Prescription Drugs Market, By Age Group

7.1. Introduction
7.2. Adult
7.3. Pediatric

8. United States Anti-obesity Prescription Drugs Market, By Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy

9. 360iResearch Competitive Strategic Window

9.1. Introduction
9.2. 360iResearch Competitive Strategic Window, by Drug Class
9.3. 360iResearch Competitive Strategic Window, by Age Group
9.4. 360iResearch Competitive Strategic Window, by Distribution Channel

10. Competitive Landscape

10.1. 360iResearch FPNV Positioning Matrix
10.1.1. Quadrants
10.1.2. Business Strategy
10.1.3. Product Satisfaction
10.2. 360iResearch Market Ranking Analysis
10.3. 360iResearch Market Share Analysis
10.4. 360iResearch Competitive Scenario
10.4.1. Merger & Acquisition
10.4.2. Agreement, Collaboration, & Partnership
10.4.3. New Product Launch & Enhancement
10.4.4. Investment & Funding
10.4.5. Award, Recognition, & Expansion

11. Company Usability Profiles

11.1. Arena Pharmaceuticals, Inc
11.2. F Hoffmann La Roche Ltd
11.3. GlaxoSmithKline
11.4. Novo Nordisk A/s
11.5. Orexigen Therapeutics, Inc

12. Appendix

12.1. Discussion Guide
12.2. Edition Details
12.3. License Details
12.4. Pricing Details

List of Figures

FIGURE 1. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RESEARCH EXECUTION
FIGURE 3. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019 VS 2025 (USD MILLION)
FIGURE 4. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 5. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2019 VS 2025 (USD MILLION)
FIGURE 6. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
FIGURE 7. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET, BY TYPE
FIGURE 8. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
FIGURE 9. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE GROWTH , 2017-2025 (USD MILLION)
FIGURE 10. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: MARKET DYNAMICS
FIGURE 11. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2019 VS 2025 (USD MILLION)
FIGURE 12. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2019 VS 2025 (USD MILLION)
FIGURE 13. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019 VS 2025 (USD MILLION)
FIGURE 14. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2025
FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025
FIGURE 17. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 18. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS

List of Tables

TABLE 1. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2017-2025 (USD MILLION)
TABLE 2. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, 2017-2025 (USD MILLION)
TABLE 3. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, 2017-2025 (USD MILLION)
TABLE 4. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, 2017-2025 (USD MILLION)
TABLE 5. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, 2017-2025 (USD MILLION)
TABLE 6. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, 2017-2025 (USD MILLION)
TABLE 7. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, 2017-2025 (USD MILLION)
TABLE 8. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, 2017-2025 (USD MILLION)
TABLE 9. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2017-2025 (USD MILLION)
TABLE 10. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2017-2025 (USD MILLION)
TABLE 11. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2017-2025 (USD MILLION)
TABLE 12. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SCORES
TABLE 13. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: BUSINESS STRATEGY
TABLE 14. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: PRODUCT SATISFACTION
TABLE 15. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RANKING
TABLE 16. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: MERGER & ACQUISITION
TABLE 17. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 18. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 19. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: INVESTMENT & FUNDING
TABLE 20. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 21. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: EDITION DETAILS
TABLE 22. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: LICENSE DETAILS
TABLE 23. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET: PRICING DETAILS

Companies Mentioned

Arena Pharmaceuticals, Inc
F Hoffmann La Roche Ltd
GlaxoSmithKline
Novo Nordisk A/s
Orexigen Therapeutics, Inc